AI assistant
Evotec SE — Regulatory Filings 2015
Oct 5, 2015
151_rns_2015-10-05_334ce1a1-f4f6-4ef6-a7b2-cabf13afed73.html
Regulatory Filings
Open in viewerOpens in your device viewer
News Details
Corporate | 5 October 2015 07:29
Evotec awarded multi-year contract to manage National Cancer Institute Chemical Biology Consortium Screening Libraries Center
DGAP-News: Evotec AG / Key word(s): Alliance
2015-10-05 / 07:29
Hamburg, Germany - 05 October 2015: Evotec AG (Frankfurt Stock Exchange:
EVT, TecDAX, ISIN: DE0005664809) today announced it has entered into a
multi-year compound management agreement with the U.S. National Cancer
Institute ("NCI"), Department of Health and Human Services. Under the terms
of the agreement, Evotec will provide compound management services to the
NCI Chemical Biology Consortium ("CBC") for a period of five years with a
total estimated value of up to EUR 4.5 m ($ 4.9 m).
The NCI Chemical Biology Consortium contract will continue to provide to
acquire, store, maintain and distribute the current library collection.
This repository will form part of the CBC's drug discovery and development
platform for new oncology therapeutics being researched by a consortium of
primarily academic and non-profit institutions.
Dr Mario Polywka, Chief Operating Officer of Evotec, commented: "We are
pleased the NCI has elected to award Evotec this important contract to
support the Chemical Biology Consortium, an important initiative in the
discovery of new cancer treatments."
ABOUT THE NCI CHEMICAL BIOLOGY CONSORTIUM (CBC)
The NCI Chemical Biology Consortium ("CBC") was established in 2009 to
facilitate the discovery and development of new agents to treat cancer. The
Consortium brings together chemical biologists and molecular oncologists
from government, industry and academia to address unmet needs in
therapeutic oncology. Through the CBC and the interactions among the
various participants, the NCI's drug discovery and development pipeline now
spans from target identification through proof-of-concept clinical trials.
The project is funded in whole with U.S. Federal funds from the National
Institutes of Health, Department of Health and Human Services, under
contract HHSN261201500010I with Evotec (US), Inc.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient advocacy
groups and venture capitalists. We operate worldwide providing the highest
quality stand-alone and integrated drug discovery solutions, covering all
activities from target-to-clinic. The Company has established a unique
position by assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and
expertise in key therapeutic areas including neuroscience, pain, metabolic
diseases as well as oncology, inflammation and infectious diseases. Evotec
has long-term discovery alliances with partners including Bayer, Boehringer
Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca,
Roche and UCB. In addition, the Company has existing development
partnerships and product candidates both in clinical and pre-clinical
development. These include partnerships with Boehringer Ingelheim and
MedImmune in the field of diabetes, with Janssen Pharmaceuticals in the
field of depression and with Roche in the field of Alzheimer's disease. For
additional information please go to www.evotec.com.
Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, [email protected]
FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this press release. Such
forward-looking statements are neither promises nor guarantees, but are
subject to a variety of risks and uncertainties, many of which are beyond
our control, and which could cause actual results to differ materially from
those contemplated in these forward-looking statements. We expressly
disclaim any obligation or undertaking to release publicly any updates or
revisions to any such statements to reflect any change in our expectations
or any change in events, conditions or circumstances on which any such
statement is based.
2015-10-05 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart
End of News DGAP News Service
399821 2015-10-05